NCT05914610View on ClinicalTrials.gov

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2028

Conditions
Gastric Cancer
Interventions
DRUG

Envolimab

Envolizumab 300mg, D1, ih, Q3W 4-6cycles

DRUG

Fruquintinib

Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles

DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles

DRUG

Tegafur

Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles

All Listed Sponsors
lead

Fujian Medical University

OTHER

NCT05914610 - Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter